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Establishing the relevance of preclinical data to the clini-
cal situation is a problem that has plagued drug devel-
opment in the majority of therapeutic areas. Typically a
drug development cascade relies on preclinical data
assuming the in vitro and in vivo data are consistent
and predict some elements of clinical efficacy. Quantita-
tive translation from preclinical to clinical is model
based and requires PK (pharmacokinetics) and PK/PD
(pharmacokinetic/pharmacodynamics) models linking
drug exposure with effect.
The first modeling step undertaken for anti-malaria
drug development at MMV has been to develop a model
capable of linking preclinical in vitro to preclinical in vivo
data to:
• Derive efficacy parameters for scaling including addi-
tional parameters that put them in context (parasite
growth rates and maximum rates of killing)
• Determine the relationship and consistency between
the in vitro and preclinical in vivo data.
This approach, whilst using data from a broader range
of compounds and mechanisms, does assume that pre-
clinical data is relevant replicating, at least partially, the
clinical disease.
The in vitro data characterized the effects of fixed con-
centrations of compound on the reduction of P falciparum
parasite concentrations and estimated IC50s. The in vivo
assessment in SCID mice determined the compound’s
dose-dependent reduction of P falciparum parasite con-
centrations and estimated an ID90. The in vivo data was
modelled using a nonlinear mixed effects PK/PD model in
Nonmem and its parameter estimates compared to those
from the in vitro data.
The modeling was performed in a step-wise approach
where a PK model was fitted to concentration time
course data from a single dose in order to simulate the
time courses used in the efficacy study (4 doses, 24
hours apart). The PK/PD model was then fitted to the
observed parasitemia data using the simulated concen-
trations. The PD model estimated baseline parasitemia,
rate constants for parasite growth and death, and the
concentration dependent moderation of parasite death.
The model determined that the parasite concentration
expanded by approximately 3-4 times every 48 hours (in
contrast to approximately 10 times in humans). For the
two compounds modeled to date, model-estimated IC50
values from the in vivo data matched the in vitro esti-
mates of IC50. The model, using the estimated para-
meters was also able to accurately simulate the decline
in parasitemia and subsequent recrudescence following
a single dose in the SCID P falciparum model providing
some mechanistic validation.
This modeling is at an early phase requiring more data,
preclinical and clinical, for validation including evaluating
methods for the prediction of clinical PK. The agreement
between in vivo and in vitro parameter estimates is
encouraging and will be confirmed as Agreement between
in vitro and in vivo parameters is encouraging as is the
model’s ability to capture parasitemia dynamics. A simple
approximation of this model is being evaluated for use in
assessing MMV’s preclinical candidates. In addition to
confirming the model’s preclinical utility, clinical data is
being sought to test whether the model is equally able in
predicting drug effects on P falciparum in humans, con-
firming the relevance of preclinical data.
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